Trademark: 97518240
Word
LIFRENZAL
Status
Pending
Status Code
688
Status Date
Tuesday, February 20, 2024
Serial Number
97518240
Mark Type
4000
Filing Date
Monday, July 25, 2022
Published for Opposition
Tuesday, December 26, 2023

Trademark Owner History
AADi Bioscience, Inc. - Owner At Publication

Classifications
5 Pharmaceutical preparations for the treatment and prevention of cancer, cardiovascular disease, epilepsy and mitochondrial disease; vaccine preparations; pharmaceutical preparations, namely, a drug formulation comprising nanoparticles of sirolimus and albumin for use in the treatment of diseases and disorders in the fields of angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, oncology, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; pharmaceutical preparations, namely, a drug formulation comprising nanoparticles of sirolimus and albumin for use in pediatric, geriatric, emergency, family, and human preventative medicine for the treatment of cancer, cardiovascular disease, epilepsy and mitochondrial disease; pharmaceutical preparations for the treatment of cancer, cardiovascular disease, epilepsy and mitochondrial disease
42 Medical and pharmaceutical research services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and scientific research, namely, conducting clinical trials for others; laboratory research services relating to pharmaceuticals; scientific and technological services, namely, scientific research services in the field of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific research and technological services consultation services in the field of development, manufacturing and testing of pharmaceuticals and biopharmaceuticals; providing product research and development in the pharmaceutical field for purposes of drug discovery process development, drug discovery validation, drug discovery qualification, and drug discovery manufacturing of pharmaceuticals and biopharmaceuticals; scientific research and technological consultation services in the field of pharmaceutical research and pharmacology; custom development of pharmaceutical, biopharmaceutical and chemical products; providing evaluation and testing for pharmaceutical, biopharmaceutical and chemical products, and medical devices featuring testing for safety, toxicity, content, identity, purity, configuration and function for others, using chemical, in vitro or in vivo assays, analyses and models; pre-clinical and non-clinical evaluation and testing of pharmaceutical, biopharmaceutical and chemical products performed primarily using animals and other biological models; pharmaceutical, biopharmaceutical, and chemical research and development for others; pharmaceutical research in the fields of angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, oncology, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; pharmaceutical research for use in pediatric, geriatric, emergency, family, and preventative medicine; pharmaceutical research for the treatment of infectious, deficiency, hereditary, and physiological diseases

Trademark Events
Feb 20, 2024
Noa E-Mailed - Sou Required From Applicant
Jan 8, 2024
Teas Change Of Correspondence Received
Jan 8, 2024
Applicant/Correspondence Changes (Non-Responsive) Entered
Jan 8, 2024
Teas Change Of Owner Address Received
Dec 26, 2023
Official Gazette Publication Confirmation E-Mailed
Dec 26, 2023
Published For Opposition
Dec 6, 2023
Notification Of Notice Of Publication E-Mailed
Nov 21, 2023
Approved For Pub - Principal Register
Nov 21, 2023
Examiner's Amendment Entered
Nov 21, 2023
Notification Of Examiners Amendment E-Mailed
Nov 21, 2023
Examiners Amendment E-Mailed
Nov 21, 2023
Examiners Amendment -Written
Aug 25, 2023
Application Extension Granted/Receipt Provided
Aug 25, 2023
Application Extension To Response Period - Received
May 26, 2023
Notification Of Non-Final Action E-Mailed
May 26, 2023
Non-Final Action E-Mailed
May 26, 2023
Non-Final Action Written
May 10, 2023
Assigned To Examiner
Aug 16, 2022
New Application Office Supplied Data Entered
Jul 28, 2022
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24